Effect of ciprofloxacin and levofloxacin on the QT interval: Is this a significant "clinical" event?

Southern Medical Journal

Volumn 99, Issue 1, 2006, Pages 52-56

  Makaryus, Amgad N ^b   Byrns, Kory ^b   Makaryus, Mary N ^b   Natarajan, Usha ^b   Singer, Carol ^b   Goldner, Bruce ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b NONE

Author keywords

Ciprofloxacin; Fluoroquinolones; Levofloxacin; QT interval; Torsade de pointes

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; ANTIINFECTIVE AGENT; OFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRONCHITIS; CALCULATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; FEMALE; HEART RATE; HUMAN; INFECTION; MALE; PNEUMONIA; PROSPECTIVE STUDY; PROSTATITIS; QT INTERVAL; QT PROLONGATION; SINUSITIS; STATISTICAL ANALYSIS; URINARY TRACT INFECTION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FOLLOW UP; HOSPITALIZATION; LONG QT SYNDROME; PATHOPHYSIOLOGY; PROGNOSIS; RESPIRATORY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG QT SYNDROME; MALE; OFLOXACIN; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATITIS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; URINARY TRACT INFECTIONS;

EID: 33644861943     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000197124.31174.7e     Document Type: Article

References (24)

1. Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. BMJ 2000;320:1158-1159.
2. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21:253S-272S.
3. Khan IA. Long QT syndrome: diagnosis and management. Am Heart J 2002;143:7-14.
4. Sedgewick ML, Lip G, Rae AP, et al. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159-166.
5. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994;47:51-65.
6. Ortho-McNeil Pharmaceutical. Levaquin (levofloxacin) package insert. Raritan, NJ; 2000.
7. Gilbert DN, Moellering RC Jr, Sande MA, Ed. Sanford Guide to Antimicrobial Therapy 2002. Thirty-second Ed. Jeb C. Sanford Publishers, Hyde Park, VT. 2002.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
9. Sorawicz B, Knoebel SB. Long QT: good, bad, or indifferent? J Am Coll Cardiol 1984;4:398-413.
10. Fuster V, Alexander RW, O'Rourke RA ed. Hurst's The Heart. 10th edition. 2001:McGraw-Hill, New York.
11. Moss AJ. Prolonged QT-interval syndromes. JAMA 1986;256:2985-2987.
12. Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385-398.
13. Chiang C, Roden DM. The long QT syndromes: Genetic basis and clinical implications. J Am Coll Cardiol 2000;36:1-12.
14. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000;45:557-559.
15. Frothingham R. Rates of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-1472.
16. Rubenstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593-596.
17. Iannini PB, Tillotson GS. Evaluating the risk of cardiac toxicity. Pharmacotherapy 2001;21:261-262.
18. Katritsis D, Camm J. Quinolones: cardioprotective or cardiotoxic? PACE 2003;26:2317-2320.
19. FDC Report. FDA/PhRMA Task Force to assess QT risk by clinical markers. The Pink Sheet-Prescription Pharmaceutical and Biotechnology 1999;61:15-16.
20. Kahn JB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect; Correspondence. J Antimicrob Chemother 2000;46:847-848.
21. Al-Khatib A, Lapointe NM, Kramer JM, et al. A survey of health care practitioners' knowledge of the QT interval. J Gen Int Med 2005;20:392-396.
22. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003;289:2120-2127.
23. Owens Jr, RC Ambrose PG. Torsade de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663-668.
24. Bayer Corporation. Cipro (ciprofloxacin) package insert. West Haven, CT; 2000.